Latest issue out now. Keep up to date on the most recent regulatory changes in the world of pharma, biotech and medical device clinical trials with ICON’s Regulatory Intelligence Newsletter. Join thousands of subscribe...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
ICON biotech sector survey: Insights and projections shaping the industry
In this article from PM360, Chris Smyth, President of ICON Biotech, summarises the main findings from the biotech sector survey and outlines the key implications for biotech including strategic collaboration, innovation and cost optimisation.
-
Capitalising on collaboration and confidence: Survey insights and expectations for biotech in 2024
This article by Chris Smyth, President, ICON Biotech, provides an overview of the recent ICON biotech sector survey findings, and looks at the trend of biotech companies engaging earlier and more comprehensively with CROs to drive efficiencies and realise the full value of their R&D programs.
-
Optimism returns as biotech optimise R&D
In this article, Brandon Early, SVP Project Delivery, outlines some of the key findings from the ICON biotech sector survey of over 130 decision makers in small, mid-size, large biotech and VC organisations.
-
ICON predicts biotech trial demand will grow despite economic pressures
This article from Clinical Insider outlines ICON’s view that the demand for clinical trial services will increase in 2024, in addition to providing an overview of the results of the recent ICON biotech sector survey, the findings of which suggest that biotech R&D spending is likely to increase.
-
48% of biotechs leaning on Big Pharma as current funding method: ICON survey
This article from Fierce Biotech provides an overview of findings from the ICON 2023 biotech sector survey, which shows that despite cash struggles, 60% of the survey respondents anticipate their R&D spend to rise over the next one to two years.
-
Due diligence and beyond
Dr. Sandra Eagle outlines how due diligence has evolved from a discrete standalone technical assessment, to now being an integrated part of the holistic development continuum of an asset.
-
Optimising biotech trial designs to stretch your cash runway
Brandon Early discusses how optimising trials designs at the earliest stages can help innovative biotech companies to maximise their available capital.
-
-
What Biotech and Pharma need to consider about decentralised trials
Discuss key considerations when implementing decentralised clinical trials, in addition to the success factors that lead to more patient-centric trials and increased patient recruitment, engagement and retention.
-
So what sectors had the most M&A activity?
This article shares how the medical and biotech sectors have dominated the mergers & acquisitions (M&A) landscape and mentions ICON’s acquisition of PRA Health Sciences. (registration required)
